Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs VanEck Semiconductor ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.54 (market cap $8.04B), while VanEck Semiconductor ETF trades at $585.61. The key difference: VanEck Semiconductor ETF is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | SMH | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | — |
52-Week High | $339.75 | $668.91 |
52-Week Low | $241.71 | $283.95 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
SMH (VanEck Semiconductor ETF) trades at $585.62, down 4.22% over 24 hours amid a sector-wide sell-off. Technical indicators show a bearish trend with support at $579 and resistance at $589. Recent news highlights strong 2026 performance but notes high expectations and recent volatility in semiconductor stocks.
The ETF's outlook is clouded by near-term volatility, though long-term AI-driven demand for semiconductors remains a tailwind. Risks include sector concentration and macroeconomic pressures, but diversification within the chip industry offers a balanced exposure for investors seeking growth in technology infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
